Comparison of two chemotherapy regimens in muscle invasive bladder cancer
1. In the perioperative setting, there was no difference between dd-MVAC vs. GC on overall 5-year survival. 2. In the...
Atezolizumab With Carboplatin in Patients With Metastatic Triple-Negative Breast Cancer
1. Progression-free survival was 4.1 months in the combination arm vs 2.2 months in the monotherapy arm with an HR...
Rituximab maintenance therapy following autologous stem cell transplant increased survival in young patients with mantle-cell lymphoma
1. In patients with mantle-cell lymphoma who responded to induction therapy and autologous stem cell transplantation, rituximab maintenance therapy prolonged...
Glucagon-like peptide 1 receptor agonists (GLP-1RAs) prescribed for type 2 diabetes are associated with reduced colorectal cancer (CRC) risk compared to other antidiabetic agents
1. In all patients, there was a 44% reduction in risk of colorectal cancer when using GLP-1RAs as compared to...
Atezolizumab Monotherapy vs Chemotherapy In Advanced Urothelial Carcinoma
1. The median overall survival was similar between both groups, 15.2 months in atezolizumab monotherapy vs 13.3 months in chemotherapy,...
Mirvetuximab soravtansine-gynx compared to chemotherapy in folate receptor alpha-positive platinum resistant ovarian cancer led to improved survival
1. Mirvetuximab soravtansine-gynx (MIRV), significantly improved progression-free survival, objective response, and overall survival compared to chemotherapy in patients with platinum-resistant,...
Tiragolumab With Atezolizumab Plus Chemotherapy in Untreated Extensive-Stage SCLC
1. Median PFS and OS between the tiragolumab and control arms were similar 2. Treatment-related AEs that were grade 3/4...
Pembrolizumab and carboplatin plus docetaxel treatment regimens may provide options for patients with triple-negative breast cancer who are ineligible for anthracycline-based regimens
1. Overall pathologic complete response to treatment of triple-negative breast cancer with a non-anthracycline regimen was 58% 2. The estimated...
Erdafitinib or Chemotherapy in Advanced Pre-Treated Urothelial Carcinoma
1. The median overall survival was 12.1 months in the erdafitinib group and 7.8 months in the chemotherapy group, with...
Selpercatinib in Advanced RET-Mutant Medullary Thyroid Cancer
1. Progression-free survival was not reached in the selpercatinib group and was 16.8 months in the control group, with an...
